A detailed history of Alphabet Inc. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Alphabet Inc. holds 698,262 shares of AUTL stock, worth $1.6 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
698,262
Previous 698,262 -0.0%
Holding current value
$1.6 Million
Previous $2.43 Million 4.32%
% of portfolio
0.17%
Previous 0.15%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Nov 14, 2022

SELL
$5.38 - $16.14 $5,864 - $17,592
-1,090 Reduced 0.16%
698,262 $11.2 Million
Q2 2019

Nov 14, 2022

SELL
$15.1 - $31.25 $222,272 - $460,000
-14,720 Reduced 2.06%
699,352 $11.3 Million
Q2 2018

Nov 14, 2022

BUY
$25.0 - $27.75 $17.9 Million - $19.8 Million
714,072 New
714,072 $19.1 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Alphabet Inc. Portfolio

Follow Alphabet Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alphabet Inc., based on Form 13F filings with the SEC.

News

Stay updated on Alphabet Inc. with notifications on news.